ARTICLE | Company News
Ophidian infectious diseases news
May 30, 2000 7:00 AM UTC
OPHD said that due to continued cash shortage, it suspended R&D operations and will seek a merger, a development partner or a purchaser of its assets. As of March 31, OPHD had $2.3 million in cash. The company also reduced its workforce from 18 to 6. OPHD lost $4.9 million on revenues of $27,000 in its fiscal year ended Sept. 30, 1999. ...